Amneal Pharmaceuticals Inc. (AMRX)
Amneal Pharmaceuticals Q2 Earnings Call Highlights
Amneal Pharmaceuticals NASDAQ: AMRX reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at its AvKARE distribution unit. The company raised its full-year revenue, adjusted EBITDA and adjusted earnings-per-share outlook, citing broad-based demand, new product launches and favorable product mix.
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.25 per share a year ago.
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase
Amneal Pharmaceuticals NASDAQ: AMRX Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches.
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Is Amneal a Buy Before Rytary Generic Erosion?
AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.
What's Driving Amneal's 2026 Growth Outlook?
AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution
Amneal Pharmaceuticals (NASDAQ:AMRX) said on Thursday the US Food and Drug Administration has approved its romidepsin injection solution, 27.5 mg/5.5 mL, in single-dose, ready-to-use vials. The product is eligible for Competitive Generic Therapy (CGT) designation, giving Amneal 180 days of market exclusivity.
